1. Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C
- Author
-
Inmaculada Fernández, Wafae Iraqi, Heiner Wedemeyer, D. Abdurakhmanov, I. Lonjon-Domanec, Christophe Moreno, M.L. Colombo, Ralph DeMasi, J.M. Läuffer, Simone I. Strasser, A. Verheyen, Petr Urbánek, Paulo Roberto Abrão Ferreira, Adrian Streinu-Cercel, and Andrew Martin Hill
- Subjects
Adult ,Liver Cirrhosis ,Male ,medicine.medical_specialty ,Cirrhosis ,Genotype ,Alpha interferon ,Hepacivirus ,Interferon alpha-2 ,Antiviral Agents ,Gastroenterology ,Drug Administration Schedule ,Polyethylene Glycols ,Telaprevir ,chemistry.chemical_compound ,Internal medicine ,Ribavirin ,medicine ,Humans ,Prospective Studies ,Aged ,business.industry ,Interferon-alpha ,virus diseases ,Hepatitis C ,Hepatitis C, Chronic ,Middle Aged ,Sciences bio-médicales et agricoles ,medicine.disease ,Rash ,Recombinant Proteins ,digestive system diseases ,Surgery ,Discontinuation ,Treatment Outcome ,Tolerability ,chemistry ,Multivariate Analysis ,Linear Models ,Drug Therapy, Combination ,Female ,medicine.symptom ,business ,Oligopeptides ,Follow-Up Studies ,medicine.drug - Abstract
Severe adverse events (AEs) compromise the outcome of direct antiviral agent-based treatment in patients with advanced liver fibrosis due to HCV infection. HEP3002 is an ongoing multinational programme to evaluate safety and efficacy of telaprevir (TVR) plus pegylated-interferon-α (PEG-IFNα) and ribavirin (RBV) in patients with advanced liver fibrosis caused by HCV genotype 1 (HCV-1)., JOURNAL ARTICLE, SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2013